Cidara Gets FDA Fast-Track for Flu Prevention Drug
By Dean Seal
Cidara Therapeutics said regulators have granted fast-track designation for CD388, its drug candidate being developed for the prevention of influenza A and B infection.
The U.S. Food and Drug Administration's designation comes after Cidara presented promising interim efficacy and safety data from an ongoing study for CD388, which the San Diego-based company is developing alongside Johnson & Johnson's Janssen Pharmaceuticals for adults at high risk of severe influenza who are unable to be vaccinated.
The FDA's fast-track designation facilitates the development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
Shares rose 3.6% to $1.14 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 22, 2023 08:53 ET (12:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom